A5075201353- Cancer-related Molecular Pathways
- Cell death mechanisms and regulation
- Cancer Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Cancer therapeutics and mechanisms
- Ubiquitin and proteasome pathways
- Colorectal Cancer Treatments and Studies
- Epigenetics and DNA Methylation
- Genetic factors in colorectal cancer
- RNA modifications and cancer
- interferon and immune responses
- Cancer Mechanisms and Therapy
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Neuroblastoma Research and Treatments
- Cancer, Lipids, and Metabolism
- Lung Cancer Research Studies
- DNA Repair Mechanisms
- FOXO transcription factor regulation
- Glioma Diagnosis and Treatment
- Cancer, Stress, Anesthesia, and Immune Response
Brown University
2016-2025
Howard Hughes Medical Institute
1998-2025
Molecular Oncology (United States)
2005-2025
University of Pennsylvania
2006-2025
John Brown University
2019-2025
Rhode Island Hospital
2020-2025
Lifespan
2019-2025
Medical College of Wisconsin
2025
Stanford University
2011-2025
University Health System
2025
The ability of p53 to activate transcription from specific sequences suggests that genes induced by may mediate its biological role as a tumor suppressor. Using subtractive hybridization approach, we identified gene, named WAF1, whose induction was associated with wild-type but not mutant gene expression in human brain cell line. WAF1 localized chromosome 6p21.2, and sequence, structure, activation conserved rodents. Introduction cDNA suppressed the growth brain, lung, colon cells culture....
Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers children and adults. We evaluated the efficacy safety larotrectinib, a highly selective TRK inhibitor, adults who had tumors with these fusions.We enrolled patients consecutively prospectively identified fusion-positive cancers, detected by molecular profiling as routinely performed at each site, into protocols: phase 1 study adults, 1-2 children, or 2 adolescents The primary end point for combined...
Circulating tumor cells (CTCs) have become an important biomarker for early cancer diagnosis, prognosis, and treatment monitoring. Recently, a replication-competent recombinant adenovirus driven by human telomerase gene (hTERT) promoter was shown to detect live CTCs in blood samples of patients. Here, we report new class adenoviruses containing regulatory elements that repress the hTERT normal cells. Compared virus with only core promoter, viruses showed better selectivity replication than...
FADD (also known as Mort-1) is a signal transducer downstream of cell death receptor CD95 called Fas). CD95, tumor necrosis factor type 1 (TNFR-1), and 3 (DR3) did not induce apoptosis in FADD-deficient embryonic fibroblasts, whereas DR4, oncogenes E1A c- myc , chemotherapeutic agent adriamycin did. Mice with deletion the gene survive beyond day 11.5 embryogenesis; these mice showed signs cardiac failure abdominal hemorrhage. Chimeric embryos showing high contribution null mutant cells to...
Significance The separation and analysis of circulating tumor cells (CTCs) provides physicians a minimally invasive way to monitor the response cancer patients various treatments. Among existing cell-separation methods, acoustic-based approaches provide significant potential preserve phenotypic genotypic characteristics sorted cells, owing their safe, label-free, contactless nature. In this work, we report development an device that successfully demonstrates isolation rare CTCs from clinical...
A MESSAGE FROM ASCO’S PRESIDENT I am pleased to present Clinical Cancer Advances 2017, which highlights the most promising advances in patient-oriented cancer research over past year. The report gives us an opportunity reflect on what exciting time it is for and how swiftly our understanding of has improved. One year ago, White House announced national Moonshot program accelerate progress against cancer. This shared vision reinvigorated community, identified new areas scientific...